Ipsen announces it is no longer eligible for the PEA-PME scheme
Ipsen announces it is no longer eligible for the PEA-PME scheme
Ipsen (Euronext: IPN; ADR: IPSEY) announces that the Group is no longer eligible for the PEA-PME scheme (a French equity savings vehicle for small and mid-sized business enterprises) as of January 1st, 2018, in accordance with Articles L221-32-2 and D221-113-5 of the French Monetary and Financial Code.
As of January 1st, 2018, the Group will no longer comply with the thresholds set by the legislator for eligibility to the PEA-PME scheme, determined on the basis of two fiscal years preceding the acquisition date of the securities i.e. the consolidated financial statements for 2016, in accordance with the French regulations.
Consequently, Ipsen Group’s securities can no longer be included in PEA-PME accounts but are still eligible for the traditional PEA scheme.

Ipsen announces it is no longer eligible for the PEA-PME scheme
Ipsen (Euronext: IPN; ADR: IPSEY) announces that the Group is no longer eligible for the PEA-PME scheme (a French equity savings vehicle for small and mid-sized business enterprises) as of January 1st, 2018, in accordance with Articles L221-32-2 and D221-113-5 of the French Monetary and Financial Code.
As of January 1st, 2018, the Group will no longer comply with the thresholds set by the legislator for eligibility to the PEA-PME scheme, determined on the basis of two fiscal years preceding the acquisition date of the securities i.e. the consolidated financial statements for 2016, in accordance with the French regulations.
Consequently, Ipsen Group’s securities can no longer be included in PEA-PME accounts but are still eligible for the traditional PEA scheme.

Related Press Releases
Ipsen delivers strong sales in the first quarter of 2026...
Ojemda® approved in the European Union as the first targeted...
Ipsen announces that Beech Tree has obtained an exemption from...
Ipsen showcases transformative potential of early immuno-oncology pipeline at AACR
Ipsen appoints Michelle C. Werner as EVP, President of North...
Ipsen voluntarily withdraws Tazverik® (tazemetostat) in follicular lymphoma and epithelioid...
Ipsen receives positive CHMP opinion for Ojemda® for the treatment...
Ipsen delivers strong results in 2025, driven by solid execution...
Ipsen nominates Peter Guenter to its Board of Directors
Pierrick Lefranc appointed as Executive Vice President Technical Operations, member...